A phase II, multicentre, non-randomised, open-label, single arm trial of the efficacy of Gemcitabine and Bexarotene in patients who have developed progressive cutaneous T-cell lymphoma (CTCL)

niversity College London (UCL) (UK)0 个研究点目标入组 84 人开始时间: 2010年3月31日最近更新: 2018年11月19日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 84

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

2013 results in: http://www.ncbi.nlm.nih.gov/pubmed/24136145

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•1. Males or non-pregnant females aged greater than 18 years
•2. Histologically confirmed diagnosis of cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome
•3. Stage Ib, IIa, IIb, III, IVa and IVb disease
•4. Patients who have failed standard skin-directed therapy and have had at least 1 course of prior systemic therapy, such as interferon, chemotherapy, Denileukin diftitox (Ontak®) which they have either failed to respond to or have subsequently progressed
•5. Anticipated life expectancy greater than six months
•6. Written informed consent to participate in the study. vii.Bexarotene naive or previous response to single-agent bexarotene, but more than 3 months since last treatment with bexarotene

排除标准

•1. Eastern Cooperative Oncology Group (ECOG) Performance Status greater than 1
•2. Patients who have not received at least 1 course of prior systemic therapy for CTCL
•3. CD30 + (Ki1+ve) anaplastic large cell lymphoma
•4. Patients who have failed previous treatment with Bexarotene (Targretin®)
•5. Patients who have previously experienced a severe adverse reaction to Bexarotene
•6. Concomitant use of any anti-cancer therapy
•7. Concomitant use of any investigational agent
•8. Use of any investigational agent within 4 weeks of study entry
•9. Clinically significant active infection
•10. Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
•11. Excessive alcohol consumption
•12. Uncontrolled diabetes mellitus
•13. Biliary tract disease
•14. History of pancreatitis
•15. Concomitant drug therapy with other medications that can elevate triglycerides or cause pancreatic toxicity e.g. Gemfibrozil
•16. Inadequate bone marrow or other organ function, as evidenced by: Unsupported haemoglobin less than 9.0 g/dL (transfusions and/or erythropoietin are permitted); Absolute neutrophil count (ANC) = 1.5 x 10^9/L; Platelet count less than 100 x 10^9/L
•17. Total bilirubin greater than 1.25 x upper limit of normal (ULN) for institution, aspartate transaminase/glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/glutamic pyruvic transaminase (ALT/SGPT) greater than 2.0 x ULN, serum creatinine greater than 2 x ULN for age and sex
•18. Coexistent second malignancy or history of prior malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin or cervical epithelial neoplasm [CIN1, carcinoma in situ] that has been treated curatively)
•19. Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures
•20. Patients who are pregnant or breast-feeding (all women of child bearing potential must use the contraceptive pill or intrauterine contraceptive device (IUCD) during the treatment period and for at least 1 month thereafter). Male patients must use a barrier method of contraception during the treatment period and for at least 1 month thereafter.
•21. Any treatment for lymphoma, including photopheresis, within the 4 weeks prior to entering the study. For patients receiving long-term corticosteroid therapy, the dose should ideally be stopped and if this is not feasible reduced to as low as possible. If steroids cannot be stopped, patients who have been on stable doses less than or equal to 20 mg for at least 3 months can be entered into the study. Local radiotherapy to isolated symptomatic tumour nodules requiring immediate treatment may be given until 2 weeks prior to entering the study.
•22. Warfarin

研究者

发起方

niversity College London (UCL) (UK)

相似试验

终止

3 期

Reactogenicity Study of Afluria Quad/Afluria Quad Junior in Childre

ACTRN12619000792123Seqirus1,056

已完成

2 期

Prevention of sagopilone-induced neurotoxicity with acetyl-L-carnitine (ALC)Ovarian cancerCancer

ISRCTN75009754Bayer Schering Pharma AG (Germany)271

进行中（未招募）

1 期

Study for the treatment of cytomegalovirus infection, in transplanted patients

EUCTR2011-001449-34-ESFUNDACION INVESTIGACION HOSPITAL CLINICO DE VALENCIA-INSTITUTO DE INVESTIGACION SANITARIA INCLIVA64

已完成

3 期

A multicentre, phase III, randomised, double-blind, placebo-controlled trial of pravastatin added to first-line chemotherapy in patients with small cell lung cancerLung cancerSmall cell lung cancerCancer

ISRCTN56306957niversity College London (UK)860

进行中（未招募）

不适用

The long-term antibody persistence of GSK Biologicals’ meningo-coccal vaccine GSK134612 in healthy adolescents/adults.Invasive disease caused by Neisseria meningitidis serogroups A, C W-135 and YMedDRA version: 18.0Level: LLTClassification code 10028910Term: Neisseria meningitides meningitisSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10051931Term: Neisseria infection NOSSystem Organ Class: 100000004862

EUCTR2012-002718-38-Outside-EU/EEAGlaxoSmithKline Biologicals749